{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dmards/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"ff583a6c-57af-5ded-8488-19039e0cd272","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 9531543a-f54c-42f4-bad6-a4c8d7294767 --><h2>Changes</h2><!-- end field 9531543a-f54c-42f4-bad6-a4c8d7294767 -->","summary":null,"htmlStringContent":"<!-- begin item ceefe057-c42c-4624-b156-63d6ba298d36 --><!-- begin field 8a5929ab-060c-4050-adb7-0426492c1112 --><p><strong>April 2020</strong> — minor update. New management scenario created to provide information regarding COVID-19. </p><p><strong>July 2018</strong> — minor update. Recommendation to carry out baseline formal ophthalmic examination within 1 year of commencing an antimalarial drug added to hydroxychloroquine monitoring. </p><p><strong>September to October 2017</strong> — reviewed. A literature search was conducted in September 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. </p><!-- end field 8a5929ab-060c-4050-adb7-0426492c1112 --><!-- end item ceefe057-c42c-4624-b156-63d6ba298d36 -->","topic":{"id":"493980c0-c660-5bda-b643-f98644c1eff8","topicId":"caed8aa7-f8ba-4a46-9441-92701c2ad78a","topicName":"DMARDs","slug":"dmards","lastRevised":"Last revised in April 2020","chapters":[{"id":"d587cd65-a186-50e3-a192-8d3f3b5c074b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e4b02852-ea41-536a-8ec9-462ecfc95b24","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"189d2086-77a0-57a3-84ed-6f44f1e56879","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ff583a6c-57af-5ded-8488-19039e0cd272","slug":"changes","fullItemName":"Changes"},{"id":"d65ec114-ec65-504e-a69b-b4fef29f3ca6","slug":"update","fullItemName":"Update"}]},{"id":"c02019ed-342b-5aa7-a645-a8c979fa0d56","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"0ee8d208-7733-5a7d-928a-41e080d05756","slug":"goals","fullItemName":"Goals"},{"id":"2206fe89-030d-5fec-adf5-ee4a379ff3a0","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ca18e3ee-b448-5d95-b060-d5ab2e909dd2","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ce5c5664-0c85-52e9-b3d1-835fa7e52c8f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ac9bf99d-b5d4-5d63-8e5c-bb174916417e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"2c23a774-3e76-52d5-8316-b8cbe2060151","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"33f76ef2-b579-5b80-985a-587d2f7cbb17","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"13df5021-0440-5dfe-b200-6910e116b50b","slug":"indications","fullItemName":"Indications"}]},{"id":"f919120c-d8c9-5fb7-b29a-fe422146fc29","fullItemName":"Management","slug":"management","subChapters":[{"id":"a22ece65-e42d-59b8-82a9-4633e64a7441","slug":"general-principles-of-managing-dmards","fullItemName":"Scenario: General principles of managing DMARDs"},{"id":"7428c7c0-3189-5d82-8d3c-61151fc43773","slug":"apremilast","fullItemName":"Scenario: Apremilast"},{"id":"c241c22b-6dd4-5334-b240-a532f0f78fd7","slug":"azathioprine","fullItemName":"Scenario: Azathioprine"},{"id":"cff5fc6d-3554-5bf8-832a-c8a089699b6f","slug":"baricitinib","fullItemName":"Scenario: Baricitinib"},{"id":"fc4f9786-0db2-5fcd-a2ca-589807093e6a","slug":"biologics","fullItemName":"Scenario: Biologics"},{"id":"a8c361a4-0693-5e57-a935-24a8383a76ba","slug":"ciclosporin","fullItemName":"Scenario: Ciclosporin"},{"id":"92b93974-10b7-5147-b0cb-e21d187093e4","slug":"cyclophosphamide","fullItemName":"Scenario: Cyclophosphamide"},{"id":"928496d4-4642-55d5-98fe-86bd350c2913","slug":"gold-intramuscular","fullItemName":"Scenario: Gold - intramuscular"},{"id":"bed27174-d641-5a3b-958e-fdb3f1b0c33f","slug":"hydroxychloroquine","fullItemName":"Scenario: Hydroxychloroquine"},{"id":"b87df30d-4917-58a4-84b5-2db454410a88","slug":"leflunomide","fullItemName":"Scenario: Leflunomide"},{"id":"29f64422-8646-5cd9-ab79-c6919331e041","slug":"methotrexate","fullItemName":"Scenario: Methotrexate"},{"id":"c4758020-9fa5-5122-9cd7-c871ebd54d73","slug":"mycophenolate-mofetil-mmf","fullItemName":"Scenario: Mycophenolate mofetil (MMF)"},{"id":"5870b3d5-8b5b-5029-86fa-0f688b740005","slug":"penicillamine","fullItemName":"Scenario: Penicillamine"},{"id":"7b2bca14-9fd5-55c7-9a3f-bb044a5c53cb","slug":"sulfasalazine","fullItemName":"Scenario: Sulfasalazine"},{"id":"4fddf07b-12b6-51d6-93db-59bb536a2db1","slug":"tacrolimus","fullItemName":"Scenario: Tacrolimus"},{"id":"1dcd6206-8d6f-548c-a253-fc19d5deb6e7","slug":"tofacitinib","fullItemName":"Scenario: Tofacitinib"},{"id":"6e4b7cba-f4a1-5221-9b40-b3adeaf750bc","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"0fcf14f9-de6c-5f14-b7e2-222e952f6aa4","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5bcf1ebc-c823-5866-8643-bb3a12bd2e78","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"99f1248a-29fc-5534-8f2a-306820d31914","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"92a3e377-bfa8-5bcb-92d5-38bd17e970e8","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bb2fda74-5193-58b7-9e0b-40e6129a4629","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"65080272-e93d-5ccb-a5f0-bcecaca6aae1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"44895091-401a-5a9b-b11f-a4e952ec6de2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"caffbaca-bd54-566b-921b-c2363a59a842","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"189d2086-77a0-57a3-84ed-6f44f1e56879","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"eefecc72-fcc4-591b-a006-9afe4a95c3bb","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 04fe0d98-7501-4808-86cf-312ef5fd674f --><h3>Previous changes</h3><!-- end field 04fe0d98-7501-4808-86cf-312ef5fd674f -->","summary":null,"htmlStringContent":"<!-- begin item 01ed642d-ee8b-4e87-9cd5-9d4430c009e5 --><!-- begin field 549c58bb-568a-4d7b-8634-9d1eb7901220 --><p><strong>July 2015 </strong>—<strong> </strong>minor update. Information about measurement of ionised calcium levels added to leflunomide monitoring requirements as per updates to the manufacturer's summary of product characteristics. </p><p><strong>July 2015 </strong>—<strong> </strong>minor update. The text regarding giving pneumococcal vaccine has been amended to be in line with regional guidelines on the monitoring of people on DMARDs.</p><p><strong>August 2014 </strong>— minor update to recommend seeking medical advice if signs or symptoms suggestive of tuberculosis appear during or after TNF-alpha blocker treatment based on the manufacturers' Summaries of Product Characteristics.  </p><p><strong>April 2014 </strong>— minor updates. Text to sulfasalazine monitoring requirements amended in line with updated information in the Summary of Product Characteristics for sulfasalazine tablets. Advice from the Medicines and Healthcare products Regulatory Agency (MHRA) regarding TNF-alpha blockers and the need to screen and monitor for tuberculosis has been incorporated.</p><p><strong>June 2013 </strong>— update to the text to reflect guidance published by the National Institute for Health and Care Excellence.</p><p><strong>January 2013 </strong>— reviewed. A literature search was conducted in December 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. Three new sections have been included on general principles of management, cyclophosphamide, and mycophenolate mofetil. Minor changes have been made to the recommendations for monitoring biologics.</p><p><strong>January 2013 </strong>— minor update. An error was found in the text regarding the monitoring requirements for methotrexate. This error has been corrected.</p><p><strong>July 2009 </strong>— minor update. Periodic skin monitoring for non-melanoma skin cancers in people with psoriasis taking anti-TNF therapy has been added to this topic. Issued in July 2009.</p><p><strong>May to August 2008 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. There are no major changes to the recommendations.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>April 2005 </strong>— written (extracted from the CKS topic on rheumatoid arthritis). Validated in June 2005 and issued in July 2005.</p><!-- end field 549c58bb-568a-4d7b-8634-9d1eb7901220 --><!-- end item 01ed642d-ee8b-4e87-9cd5-9d4430c009e5 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}